Current Knowledge of Pain After Breast Cancer Treatment: A Systematic Review

Cooney, Marese; Culleton-Quinn, Elizabeth; Stokes, Emma

doi:10.1016/j.pmn.2010.09.002

Cited by 29 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two main factors present at 1 month following surgery were predictive of ongoing pain problems at 21 months: arm symptoms and emotional function. The prevalence of pain at 21 months following surgery reported in our study is consistent with previous findings [2,8] as were the rates of moderate-to-severe persistent pain [8,10,27]. However, our findings differed to those of Andersen et al [11] who reported lower rates of moderate-to-severe pain in their cohort at rest and during movement at 1 year followup.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Prevalence and risk factors associated with pain 21 months following surgery for breast cancer

Moloney

Sung

Kilbreath

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

“…With 5-year survival rates reaching 90 % [1], the emphasis now needs to focus on quality of life following treatment. Persistent pain following treatment for BC may affect up to 60 % of women treated for BC [2]. Pain is associated with lower quality of life [3,4], higher disability [5], and emotional and psychological distress [5].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and risk factors associated with pain 21 months following surgery for breast cancer

Moloney

Sung

Kilbreath

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…This might have led to a inclusion of patients who were more difficult to treat in primary care and (4) we included 108 patients with suspected peripheral nerve damage. Almost 60% of the patients after treatment for breast cancer has pain [ 56 ]. Based on the recent review by Ilhan et al [ 57 ], in patients who reported pain following breast cancer treatment the pooled prevalence of neuropathic pain from screening questionnaires ranged from 32.6 to 58.2%.…”

Section: Discussionmentioning

confidence: 99%

Avoiding Catch-22: validating the PainDETECT in a population of patients with chronic pain

et al. 2018

View full text Add to dashboard Cite

BackgroundNeuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system and is a major therapeutic challenge. Several screening tools have been developed to help physicians detect patients with neuropathic pain. These have typically been validated in populations pre-stratified for neuropathic pain, leading to a so called “Catch-22 situation:” “a problematic situation for which the only solution is denied by a circumstance inherent in the problem or by a rule”. The validity of screening tools needs to be proven in patients with pain who were not pre-stratified on basis of the target outcome: neuropathic pain or non-neuropathic pain. This study aims to assess the validity of the Dutch PainDETECT (PainDETECT-Dlv) in a large population of patients with chronic pain.MethodsA cross-sectional multicentre design was used to assess PainDETECT-Dlv validity. Included where patients with low back pain radiating into the leg(s), patients with neck-shoulder-arm pain and patients with pain due to a suspected peripheral nerve damage. Patients’ pain was classified as having a neuropathic pain component (yes/no) by two experienced physicians (“gold standard”). Physician opinion based on the Grading System was a secondary comparison.ResultsIn total, 291 patients were included. Primary analysis was done on patients where both physicians agreed upon the pain classification (n = 228). Compared to the physician’s classification, PainDETECT-Dlv had a sensitivity of 80% and specificity of 55%, versus the Grading System it achieved 74 and 46%.ConclusionDespite its internal consistency and test-retest reliability the PainDETECT-Dlv is not an effective screening tool for a neuropathic pain component in a population of patients with chronic pain because of its moderate sensitivity and low specificity. Moreover, the indiscriminate use of the PainDETECT-Dlv as a surrogate for clinical assessment should be avoided in daily clinical practice as well as in (clinical-) research. Catch-22 situations in the validation of screening tools can be prevented by not pre-stratifying the patients on basis of the target outcome before inclusion in a validation study for screening instruments.Trial registrationThe protocol was registered prospectively in the Dutch National Trial Register: NTR 3030.Electronic supplementary materialThe online version of this article (10.1186/s12883-018-1094-4) contains supplementary material, which is available to authorized users.

show abstract

“…Breast cancer represents a malignant cancer with serious consequences for the female population ( 1 – 3 ). There have been >400,000 breast cancer related mortalities per year in the pastdecade ( 4 – 6 ).…”

Section: Introductionmentioning

confidence: 99%

IL-32 promotes breast cancer cell growth and invasiveness

2014

View full text Add to dashboard Cite

Interleukin (IL)-32 is a newly identified cytokine in humans and primates. It has been established that IL-32 may antagonize cancer growth. However, to the best of our knowledge, the direct effect of IL-32 on breast cancer cell growth has not yet been investigated. In addition, rodents lack the expression of IL-32; hence, the effects of IL-32 on breast cancer xenografts in nude mice have not been studied. The present study aimed to examine the potential regulatory effects of IL-32 on breast cancer cells in nude mice. The effects of IL-32 on tumor cell growth in cell cuture and a tumor xenograft model were investigated, as well as the effects of IL-32 on apoptosis. The effects of IL-32 on cell proliferation and apoptosis were investigated by MTT assay and TUNEL staining, respectively. The results revealed that IL-32 increases the proliferation rate of cancer cells and decreases the rate of apoptosis, In addition, IL-32 was found to enhance the growth of tumor xenografts in vivo. In summary, IL-32 may represent a useful therapeutic target for human breast cancer.

show abstract

Current Knowledge of Pain After Breast Cancer Treatment: A Systematic Review

Cited by 29 publications

References 35 publications

Prevalence and risk factors associated with pain 21 months following surgery for breast cancer

Prevalence and risk factors associated with pain 21 months following surgery for breast cancer

Avoiding Catch-22: validating the PainDETECT in a population of patients with chronic pain

IL-32 promotes breast cancer cell growth and invasiveness

Contact Info

Product

Resources

About